Serial No. 756,025

24. A pharmaceutical composition comprising a compound of formula (1) described in claim 19 in association with a pharmaceutically acceptable carrier.

25. A method of producing muscel relaxation in a mammal which comprises parenterally administering to a mammal an effective muscle relaxation amount of a compound of claim 19.

26. The method of claim 25 in which the compound is administered in a pharmaceutically acceptable carrier.

27. A compound of claim 19/where X is C1.

28. A mixture according to claim 23 wherein X is C1.

29. A composition accombing to claim 24 wherein X is C1.

30. A method according to claim 25 wherein X is C1.

31. 2,2°[(E)-4-Octehedioylbis(oxytrimethylene)]bis[18,28-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinum] cation in association with a pharmaceutically acceptable anion.

32. (E)-(1R, 1'R, 2R, 2'8)-2, 2'-[4-Octenedicylbis(oxytrimethylene)]bis[1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1-(3, 4, 5-trimethoxybenzyl)isoquinolinium] cation in association with a pharmaceutically acceptable anion.

33.

2, 2! - [(g) - 4 - 0ctenedioylbis) oxytrimethylene) ] bis [(1R, 2g) - 1, 2, 3, 4 - tetrahydro-6-, 7 - dimethoxy-2 - methyl - 1 - (3, 4, 5 - trimethoxybenzyl) isoquinolinium] cation in association with a

Mp1

Serial No. 756,025

pharmaceutically acceptable anion.

34. A method for producing muscle/relaxation in a mammal which comprises parenterally administering to a mammal an effective muscle relaxant amount of one or more of the compounds of claims 31, 32 or 33.

35. A pharmaceutical composition comprising one or more of the compounds of claims 31, 32 and a pharmaceutically acceptable carrier therefor.

36. A compound of claims 31, 32 or 33 in which the anion is the chloride anion.

37. 2, 2' [( $\underline{E}$ )-4-Octehedioylbis (oxytrimethylene)]bis[1 $\underline{R}$ , 2 $\underline{R}$ -1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1-(3, 4, 5-trimethoxybenzyl)isoquinolinum] dichloride.

38.  $(\underline{E}) - (1\underline{R}, 1^{\dagger}\underline{R}, 2\underline{R}, 2^{\dagger}\underline{S}) - 2, 2^{\dagger} - [4 - 0 \text{ctenedioy1bis}(o \text{xytrimethylene})]$  bis[1, 2, 3, 4 - tetrahydro - 6, 7 - dimethoxy - 2 - methyl - 1 - (3, 4, 5 - trimethoxybenzylisoquinolinium] dichloride.

39. 2, 2'-[ $\langle \underline{E} \rangle$ -4-Octenedicylbis) oxytrimethylene)]bis[ $(1\underline{R}, 2\underline{S})$ -1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1-(3, 4, 5-trimethoxybenzyl) isoquinolinium] dichloride.

40. A method for producing muscle relaxation in a mammal which comprises parenterally administering to a mammal an effective muscle relaxant amount of one or more of the compounds of claims 19, 20 or 21.

41/ A sterile pharmaceutical composition comprising one or